文献速递心外重症与机械循环支持

在门诊心室辅助装置时代,是否应重新考虑较大儿童门诊正性肌力药物桥接心脏移植的做法?

In the era of outpatient ventricular assist devices, is it time to reconsider the practice of bridging older children to transplant on outpatient inotropes?
PubMed 文献 · J Thorac Cardiovasc Surg · 2023-06-14

研究利用美国器官共享网络2012至2022年数据,纳入835例门诊等待心脏移植的18岁及以下、体重>25 kg患者,按桥接方式分为心室辅助装置(VAD)组235例、正性肌力药物组176例和无支持组424例。VAD组移植时功能状态优于正性肌力药物组(性能量表>70%:59% vs 31%,P<.001),且晚期移植后生存更优。

要点

  • 门诊VAD桥接者移植时功能状态>70%的比例为59%,高于正性肌力药物组的31%(P<.001)。
  • VAD组总体移植后1年及5年生存率分别为97%和88%,与无支持组(93%和87%)及正性肌力药物组(98%和83%)相比均无显著差异(P=.090和P=.089)。
  • VAD组1年条件生存优于正性肌力药物组(2年及6年生存率96%和91% vs 97%和79%,P=.030),5年条件生存优于正性肌力药物组(7年及10年生存率100%和100% vs 100%和88%,P=.022)及无支持组(100%和83%,P=.011)。

核心结论

  • 与既往研究一致,门诊环境下以VAD或正性肌力药物桥接至心脏移植的儿科患者短期结局极佳。
  • 与门诊正性肌力药物桥接相比,门诊VAD支持可使移植时功能状态更好,并带来更优的晚期移植后生存。

研究设计与样本

  • 利用美国器官共享网络(United Network for Organ Sharing)识别2012年至2022年间年龄18岁及以下、体重>25 kg、移植时为门诊状态的患者,共835例。
  • 按移植时桥接方式分组:VAD组235例(28%)、正性肌力药物组176例(21%)、无支持组424例(50%)。

主要发现

  • VAD组与正性肌力药物组年龄相似(P=.260),但体重更重(P=.007),且扩张型心肌病比例更高(P<.001)。
  • VAD组移植时临床状态与正性肌力药物组相似,但功能状态(性能量表>70%)更优(59% vs 31%,P<.001)。
  • VAD组总体移植后1年及5年生存率分别为97%和88%,与无支持组(93%和87%)相比P=.090,与正性肌力药物组(98%和83%)相比P=.089。
  • VAD组1年条件生存优于正性肌力药物组:2年及6年生存率分别为96%和91% vs 97%和79%(P=.030)。
  • VAD组5年条件生存优于正性肌力药物组(7年及10年生存率100%和100% vs 100%和88%,P=.022)及无支持组(100%和83%,P=.011)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Ventricular assist devices (VADs) and inotropes are feasible modalities to bridge children to heart transplant (HT) in outpatient settings. However, it is unclear which modality yields superior clinical status at HT and posttransplant survival. METHODS: The United Network for Organ Sharing was used to identify patients aged 18 years or younger, weighing >25 kg, from 2012 to 2022 who were outpatients at HT (n = 835). Patients were grouped by bridging modality at HT: VAD (n = 235 [28%]), inotropes (n = 176 [21%]), or neither (no support) (n = 424 [50%]). RESULTS: VAD patients were of similar age (P = .260) but heavier (P = .007) and more likely to have dilated cardiomyopathy (P < .001) than their inotrope counterparts. VAD patients had similar clinical status at HT but superior functional status (performance scale >70%) (59% vs 31%) (P < .001). Overall posttransplant survival in VAD patients (1-year and 5-year survival, 97% and 88%, respectively) was comparable to patients with no support (93% and 87%, respectively) (P = .090) and those on inotropes (98% and 83%, respectively) (P = .089). One-year conditional survival was superior for VAD vs inotrope (2-year and 6-year survival, 96% and 91%, respectively vs 97% and 79%, respectively) (P = .030) and 5-year conditional survival for VAD patients was superior to inotrope (7-year and 10-year survival, 100% and 100%, respectively vs 100% and 88%, respectively) (P = .022) and no support (100% and 83%, respectively) (P = .011). CONCLUSIONS: Consistent with prior studies, short-term outcomes for pediatric patients bridged to HT in the outpatient setting with VAD or inotropes is excellent. However, compared with outpatients bridged to HT on inotropes, outpatient VAD support allowed for better functional status at HT and superior late posttransplant survival.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Guzman-Gomez A, Greenberg JW, Dani A, et al. In the era of outpatient ventricular assist devices, is it time to reconsider the practice of bridging older children to transplant on outpatient inotropes? J Thorac Cardiovasc Surg. 2023. PMID: 37321290. doi:10.1016/j.jtcvs.2023.06.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。